Talphera
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1850 Gateway Dr Ste 175, San Mateo, Cali...Phone Number
(650) 216-3500Website
www.talphera.comRevenue
<$5 MillionStock Symbol
TLPHIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.Explore more
Talphera Org Chart
Get the full picture
Sign in to uncover key details.
LR
Director, Clinical Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Talphera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Talphera had a recent Job posting/layoffs
Product Launch: Get notified when Talphera launches new products
Congratulate Masked Content for being promoted to Masked Content at Talphera
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Talphera is spiking on competitors!
Talphera, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Talphera has new funding data
Check if Talphera has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Talphera recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Talphera is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Talphera is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Talphera.
Talphera financials insights
Gather financial insights about Talphera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$29M
Private Equity
$17M
Most Recent Scoops
Person-Based
Funding
Funding
Funding
Funding
Earnings
reported cash operating expenses of $3.7 million for the second quarter of 2025, compared to $4.3 million for the same period in 2024. Excluding non-cash stock-based compensation, these amounts were $3.5 million and $4 million respectively.
Project
Talphera News & Media
Talphera Q1 2026 Earnings Call Transcript
Talphera (NASDAQ:TLPH) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://app.webinar.net/8B95lMZwZmO Summary Talphera Inc has made significant progress in their Nefro CRRT study, surpassing the 50% enrTalphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH),...Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first...TALPHERA CMO surrenders 2,118 shares for taxes | TLPH Insider Trading - Stock Titan
TALPHERA Chief Medical Officer Aslam Shakil surrendered 2,118 shares at $0.7223 to cover RSU tax withholdings, leaving 81,060 common shares directly held.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Talphera
Sign Up For FreeTo access detailed company insights
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also de... Read More
